Cardiovascular-Kidney-Metabolic Disease
Spherix delivers actionable insights across obesity, MASH, and chronic kidney disease, helping biopharma teams understand how evolving treatment approaches, stakeholder behaviors, and market dynamics are shaping these rapidly changing markets.
As GLP-1 and SGLT2, MRA and other new therapies deliver benefits that cut across metabolic, renal, and cardiovascular endpoints at once, understanding how prescribers and payers are actually navigating overlapping conditions and fragmented care across these therapies, before it shows up in share data, is what separates brands that win market position from brands that defend it.
Subscribe for CKM disease updates
About Cardiovascular-Kidney-Metabolic Disease
Innovation across obesity, MASH, and chronic kidney disease is reshaping treatment expectations and creating new considerations for physicians, patients, payers, and biopharma companies. As new therapies expand treatment options and established classes – especially GLP-1 agonists and SGLT-2 inhibitors – find broader roles across indications, understanding how stakeholders respond to a changing landscape is increasingly important.
Spherix provides independent, specialty-focused insights into these evolving markets, helping clients understand treatment behavior, emerging opportunities and barriers, and the factors influencing adoption and access.
INDICATIONS COVERED
- Chronic Kidney Disease, Non-Dialysis (CKD-ND)
- Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- Obesity
Cardiometabolic and renal care are being redrawn by a single class of therapies. GLP-1 receptor agonists, first established in diabetes and obesity, are now demonstrating meaningful cardiovascular and kidney protection. SGLT2 inhibitors, with the same origin, have become foundational therapy in chronic kidney disease and heart failure. And MASH, long defined by unmet need, shares underlying metabolic drivers and an overlapping patient population with obesity and diabetic/chronic kidney disease. The result is a set of conditions that used to sit in separate franchises, and separate budgets, now competing for the same prescribers, the same payer policies, and increasingly the same patients.
Spherix has tracked this cardiometabolic/renal overlap for years and has launched dedicated coverage in 2026, working with leading and emerging biopharma companies shaping innovation across obesity, MASH, and kidney disease. The Spherix community of practicing endocrinologists, hepatologists, nephrologists, and/or cardiologists are continuously screened for active practice and patient volume. Spherix publishes multiple studies annually across physician, patient, and payer perspectives.
The insights that inform confident, strategic decisions
The Spherix three-perspective lens applied to cardiovascular-kidney-metabolic disease:
physician
How are prescribers sequencing an increasingly crowded cardiometabolic stack across obesity, CKD, and MASH as GLP-1, SGLT2, and MRA therapies cut across all three diseases? Where does ownership of the CKM patient sit across primary care, endocrinology, nephrology, hepatology, and cardiology? How is treatment intent evolving as risk reduction for interrelated metabolic conditions becomes a driver of therapy choice?
Patient
Where do patient and physician views on treatment burden, tolerability, and durability diverge across obesity, CKD, and MASH? How does asymptomatic kidney disease change that calculus when patients are asked to tolerate side effects for benefits they cannot feel? And, how is GLP-1 demand in one condition reshaping expectations in the others?
payer (market access)
How are payers coordinating, or fragmenting, coverage for cardiometabolic therapies that now span endocrinology, nephrology, hepatology, and cardiology? Where do prior-authorization criteria and cash-pay dynamics diverge by indication for the same molecule? And, do kidney-protective agents get credit for delaying dialysis or get judged on drug spend alone?
Spherix clients have exclusive access to
Research products
Therapeutic expertise and advisory
Customization and targeting
AI-assisted synthesis
Related Articles
Meet the Team
